Lorus Therapeutics Inc. (LOR) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 25 PAGES: 45

More Info
									         Lorus Therapeutics Inc. (LOR) - Financial and Strategic SWOT Analysis
                                         Review
        Reference Code: GDPH61222FSA                                                                                           Publication Date: JUL 2013

          2 Meridian Road                                    Phone              +1 416 7981200                  Revenue          NA
          Toronto, ON                                        Fax                +1 416 7982200                  Net Profit       -4.61 (million CAD)
          M9W 4Z7                                            Website            www.lorusthera.com              Employees        12
                                                                                LOR [Toronto         Stock                       Pharmaceuticals           &
          Canada                                             Exchange                                           Industry
                                                                                Exchange]                                        Healthcare

       Company Overview
       Lorus Therapeutics Inc. (Lorus), formerly known as Imutec Pharma Inc., is a life sciences company. It focuses on the discovery,
       research and development of anticancer therapies.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Lorus Therapeutics Inc., SWOT Analysis
         Dr. Aiping H. Young                 Chief Executive Officer                  Strengths                              Weaknesses
         Dr. Denis R. Burger                 Director
                                                                                      Research and Development               Manufacturing Capabilities
         Herbert Abramson                    Director
                                                                                      Product Pipeline
         Warren Whitehead                    Director
         Dr. Mark Vincent                    Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Growing Prostate Cancer                Intense Competition
       Share Data                                                                     Market
                                                                                                                             Uncertainties in R&D
         Lorus Therapeutics Inc.
                                                                                      Demographic Trends
        Share Price (CAD) as on 26-Jul-                                  0.17
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (CAD)                                                       -0.23        GlobalData
        Market Cap (million CAD)                                            7
        Enterprise Value (million CAD)                                      4
        Shares Outstanding (million)                                       42
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Jul 15, 2013         Lorus Therapeutics Reports Results for Fiscal
                                                                                                           Year 2013
                                                                                      Jun 26, 2013         Lorus Therapeutics Appoints Dr.                 Brad
                                                                                                           Thompson To The Board Of Directors
                                                                                      Apr 12, 2013         Lorus Therapeutics Reports Q3 Fiscal 2013
                                                                                                           Results
                                                                                      Jan 14, 2013         Lorus Therapeutics Reports Q2 Fiscal 2013
                                                                                                           Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Lorus Therapeutics Inc. (LOR) - Financial and Strategic SWOT                                                                   Reference Code: GDPH61222FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Lorus Therapeutics Inc. - Key Facts ................................................................................................................................................... 5
       Lorus Therapeutics Inc. - Key Employees .......................................................................................................................................... 6
       Lorus Therapeutics Inc. - Key Employee Biographies ........................................................................................................................ 7
       Lorus Therapeutics Inc. - Major Products and Services ..................................................................................................................... 8
       Lorus Therapeutics Inc. - Pharmaceutical Pipeline Products Data ..................................................................................................... 9
          Lorus Therapeutics Inc., Pipeline Products by Therapy Area ......................................................................................................... 9
          Lorus Therapeutics Inc., Pipeline Products by Development Phase............................................................................................. 10
       Lorus Therapeutics Inc. - History ...................................................................................................................................................... 13
       Lorus Therapeutics Inc. - Company Statement ................................................................................................................................ 16
       Lorus Therapeutics Inc. - Locations And Subsidiaries ...................................................................................................................... 17
          Head Office ................................................................................................................................................................................... 17
          Other Locations & Subsidiaries ..................................................................................................................................................... 17
       Section 2 – Company Analysis ......................................................................................................................................................... 18
       Lorus Therapeutics Inc. - Business Description ............................................................................................................................... 18
       Lorus Therapeutics Inc. - Corporate Strategy................................................................................................................................... 19
       Lorus Therapeutics Inc. - SWOT Analysis ........................................................................................................................................ 20
          SWOT Analysis - Overview........................................................................................................................................................... 20
          Lorus Therapeutics Inc. - Strengths .............................................................................................................................................. 20
             Strength - Research and Development ..................................................................................................................................... 20
             Strength - Product Pipeline ....................................................................................................................................................... 20
             Strength - Strategic Alliances .................................................................................................................................................... 20
          Lorus Therapeutics Inc. - Weaknesses ......................................................................................................................................... 20
             Weakness - Manufacturing Capabilities .................................................................................................................................... 20
          Lorus Therapeutics Inc. - Opportunities ........................................................................................................................................ 21
             Opportunity - Growing Prostate Cancer Market ........................................................................................................................ 21
             Opportunity - Demographic Trends ........................................................................................................................................... 21
             Opportunity - Orphan Drug Designation .................................................................................................................................... 21
          Lorus Therapeutics Inc. - Threats ................................................................................................................................................. 21
             Threat - Intense Competition ..................................................................................................................................................... 21
             Threat - Uncertainties in R&D ................................................................................................................................................... 21
             Threat - Stringent Government Regulations .............................................................................................................................. 22
       Lorus Therapeutics Inc. - Key Competitors ...................................................................................................................................... 23
       Section 3 – Company Financial Ratios ............................................................................................................................................. 24
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 24
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 24
       Performance Chart ........................................................................................................................................................................... 26
       Financial Performance...................................................................................................................................................................... 26
       Financial Ratios - Interim Ratios....................................................................................................................................................... 27
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 28
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 29
          Lorus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013....................................................... 29


Lorus Therapeutics Inc. (LOR) - Financial and Strategic SWOT                                                                                                   Reference Code: GDPH61222FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Lorus Therapeutics Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ...................................................... 30
       Lorus Therapeutics Inc., Recent Deals Summary ............................................................................................................................ 31
       Section 5 – Company’s Recent Developments ................................................................................................................................ 32
          Lorus Therapeutics Inc., Recent Developments ........................................................................................................................... 32
             Jul 15, 2013: Lorus Therapeutics Reports Results for Fiscal Year 2013 ................................................................................... 32
             Jun 
								
To top